HPD Research Day | February 16, 2018

48 Objective. The purpose of this cross-sectional study is to evaluate the perception of clinical pharmacists by prescribers within a primary care-based ACO. Background. The Alternative Payment Model (APM) is a payment approach that incentivizes high quality patient care. It includes the Medicare Shared Savings Program and the Next Generation Accountable Care Organization (ACO) Model. Within primary care-based, clinical pharmacists are in an ideal position to manage multiple aspects of patient care. Methods. A qualitative, anonymous survey consisting of seventeen items divided into four domains was created and disseminated electronically and/or by hand to prescribers within two Accountable Care Organizations in South Florida. Survey construction was performed utilizing information retrieved during the literature search as well as consulting the expert opinions of current pharmacists who work within the APM models. The survey was then given to six pharmacy faculty, two physicians, one Director of Quality Improvement who work within the ACO model to screen for readability. Results. 11 prescribers completed the survey with 81.8% of prescribers having had the opportunity to collaborate with clinical pharmacy services. Overall, prescribers were more likely to refer patients with chronic conditions to clinical pharmacy services. Almost all of the prescribers who took the survey believed clinical pharmacists help to improve patient quality outcomes (90.9%). However, 5 of 11 (45.5%) surveyed prescribers felt comfortable signing a Collaborative Practice Agreement (CPA) with a clinical pharmacist. Conclusion. Although clinical pharmacists were perceived as having high value in the ACO setting, many prescribers were not comfortable signing a CPA. Atrium – Poster 40 12:15-1:15 p.m. Evaluation of the Cytotoxic Profile of Metformin and Y15 in Platinum Resistant Ovarian Cancer Cells Zara Khan, OMS-II, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University Arkene Levy, Ph.D., Associate Professor, College of Medical Sciences, Nova Southeastern University Appu Rathinavelu, Ph.D., Professor and Director, Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University Keerthi Thallapureddy, Halmos College of Natural Sciences and Oceanography, Nova Southeastern University Objectives. This study evaluated the combined cytotoxic efficacy of metformin and the focal adhesion kinase (FAK) inhibitor Y15, in platinum resistant OVCAR3 ovarian cancer cells. Background. In previous studies, we demonstrated that metformin, an antidiabetic drug, induces cytotoxicity in platinum resistant ovarian cancer cells. Increased phosphorylation of FAK, a tyrosine kinase, is implicated in the development of this platinum resistance. We therefore evaluated the ability of metformin to enhance FAK inhibition in vitro. Methods. Cells were treated with Y15 (10-100 μM) and metformin (10-100Mm) separately, to determine IC 10 values which were used for combination protocols (Y15 20μM + Metformin (10Mm). Following treatment, DNA fragmentation and poly ADP ribose polymerase (PARP) cleavage assays were used to evaluate mechanisms of cell death. Total and phosphorylated FAK, p53, p21, and BAX expression were also assessed using western blot. Results. Y15 significantly increased the efficacy of metformin compared to metformin only. Apoptotic cell death was confirmed by PARP cleavage and DNA fragmentation. Combination treatment with metformin and Y15 downregulated phosphorylated FAK expression, confirming reduced FAK activity. Reduced FAK phosphorylation correlated with increased expression of pro-apoptotic markers p53, p21 and BAX. Conclusions: Y15 enhances the cytotoxic profile of metformin in platinum resistant OVCAR 3 cells. This study is the first to report a FAK dependent cytotoxic mechanism of metformin in ovarian cancer. In further work, we will explore the mechanisms by which metformin increases Y15 mediated FAK inhibition. Grants. The authors thank the Royal Dames Inc. Ft. Lauderdale for financial support. Atrium – Poster 41 12:15-1:15 p.m. Dysfunctional Movement Patterns Differ Between Male and Female NCAA Division II Athletes Daniel Klahr, Dr. Pallavi Patel College of Health Care Sciences, Nova Southeastern University Monique G. Mokha, Ph.D., Director/Associate Professor, Dr. Pallavi Patel College of Health Care Sciences, Nova Southeastern University Objective. This study was conducted to determine differences in dysfunctional movement pattern frequency, as measured by a score of “1” on the Functional Movement Screen (FMS) between male and female collegiate athletes. Background. The FMS consists of 7 tests (scored 1-3 on proficiency) assessing foundational patterns such as